C2CD4A: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: C2CD4A

NCBI ID: G145741

C2CD4A

C2CD4A: A Promising Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of current pain treatments to provide lasting relief has led to a growing interest in identifying new approaches to manage chronic pain. C2CD4A, a protein known as FAM148A, has emerged as a promising drug target and biomarker for the management of chronic pain. This article will provide an overview of C2CD4A, its potential as a drug target and biomarker, and its potential clinical applications.

C2CD4A: The Protein that Wants to be a Drug Target

C2CD4A, also known as FAM148A, is a protein that is expressed in various tissues and cells in the body. It is a member of the PDZ/PQR family of proteins, which are known for their role in intracellular signaling. C2CD4A is unique in that it has a long N-terminus that is highly conserved across various species, including humans. This conserved region is involved in the formation of a protein-protein interaction (PPI) complex, which is a critical step in the regulation of cellular processes.

C2CD4A has been shown to play a role in pain signaling. It is involved in the development of pain neuroplasticity, which is the ability of the brain to adapt to chronic pain. C2CD4A has also been shown to regulate the release of endogenous opioids, such as enkeji and oxirapidine, which are involved in pain modulation. These findings suggest that C2CD4A may be a useful drug target for the management of chronic pain.

C2CD4A as a Biomarker

One of the challenges in the development of new pain treatments is the lack of objective biomarkers that can predict the effectiveness of new treatments. C2CD4A may provide such a biomarker, as it has been shown to be expressed in response to pain stimuli and has been linked to the development of pain.

C2CD4A has been shown to increase in the levels of various genes in the body in response to pain stimuli. For example, when mice were treated with pain-inducing agents, C2CD4A was found to be upregulated in the genes involved in pain signaling. This increase in C2CD4A levels may indicate that the pain stimuli were effective in modulating the expression of C2CD4A.

C2CD4A may also be used as a biomarker for tracking the efficacy of pain treatments. For example, if a new pain treatment is shown to be effective, C2CD4A levels may be expected to decrease over time. This decrease in C2CD4A levels could serve as a marker for the effectiveness of the treatment.

C2CD4A as a Drug Target

The potential use of C2CD4A as a drug target makes it an attractive candidate for the development of new pain treatments. By targeting C2CD4A, new drugs could be designed to reduce pain levels and improve quality of life.

One approach to targeting C2CD4A is to use small molecules (such as drugs or chemical compounds) that can modulate the activity of C2CD4A. Such compounds have been shown to be effective in reducing pain in various animal models. For example, a compound called SM-801 has been shown to be an effective inhibitor of C2CD4A, reducing pain in mouse models of chronic pain.

Another approach to targeting C2CD4A is to use antibodies that can bind to C2CD4A and prevent it from interacting with its downstream targets. This approach has been shown to be effective in animal models of

Protein Name: C2 Calcium Dependent Domain Containing 4A

Functions: May be involved in inflammatory process. May regulate cell architecture and adhesion

The "C2CD4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2CD4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets